Compugen Ltd at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hey, everybody, it's Alethea Young here. I cover large cap, small mid-cap biotech at Cantor. Very happy to have Compugen here with us. We have Anat Cohen-Dayag, who is the President and CEO -- Dr. Anat Cohen-Dayag, let me correct myself. Dr. Henry Adewoye, SVP and CMO, and Ari Krashin, who is the CFO and COO.
We will be doing a fireside chat. And I'm sure everybody will kind of take turns of answering different questions that come along the way. So I just wanted to maybe take a minute and just have Anat talk about the big picture story of Compugen and what kind of accomplishments you've seen over the past 12 months, which I think are a good amount, actually.
Sure, thank you, Alethia, and thank you for inviting us to your conference. So Compugen is a therapeutic discovery and development company. We discover new drug targets, and we develop first-in-class drugs to address these drug targets. We are discovering new drug targets
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |